Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d 1‐specific immunotherapy using high‐dose CpG adjuvant
Allergy2020Vol. 76(7), pp. 2153–2165
Citations Over TimeTop 20% of 2020 papers
Catherine Léonard, Guillem Montamat, Caroline Davril, Olivia Domingues, Oliver Hunewald, Dominique Revets, Coralie L. Guérin, Simon Blank, Justine Heckendorn, Gauthier Jardon, François Hentges, Markus Ollert
Abstract
Our results highlight the potential of CpG adjuvant in a novel formulation to be further exploited for inducing allergen-specific tolerance in patients with cat allergy or other allergic diseases.
Related Papers
- → Adjuvant activity of CpG-ODN formulated as a liquid crystal(2014)31 cited
- → Immunological Efficacy and Safety of Synthesized CpG Oligodeoxynucleotides(2018)1 cited
- Research progress of the novel adjuvant CpG ODN(2014)
- Progress on Vaccine Adjuvant CpG ODN(2011)
- → Research progress in vaccine adjuvant CpG ODN(2017)